Watch for CLN-978 multi-dose data in December 2026 across three autoimmune indications, which could be a pivotal catalyst for the CD19 TCE platform. Velinotamig data at ACR in November may provide early read on BCMA TCE activity in SLE. CLN-049 Phase 1 update and potential registrational Phase 2 initiation are key for oncology pipeline valuation.
Price Chart
Executive Summary
Cullinan Therapeutics announced upcoming Q4 2026 pipeline milestones for its T cell engager programs, including multi-dose data for CLN-978 in SLE, RA, and Sjögren's disease, velinotamig data at ACR Convergence, and updated CLN-049 data in AML. The press release also reported Q2 2026 EPS of -$0.81, a 4.1% beat versus consensus of -$0.84, with no revenue. The pipeline catalysts are notable but the company remains pre-revenue with no financial guidance changes.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.81 beat consensus of -$0.84 by 4.1%
- No revenue reported for Q2 2026
- CLN-978 multi-dose regimen data in SLE, RA, and Sjögren's disease expected in December 2026
- Velinotamig multi-dose data in SLE to be presented at ACR Convergence 2026 on November 8, 2026
- CLN-049 updated Phase 1 dose escalation data in AML expected in December 2026
- Company plans to initiate potentially registrational Phase 2 study for CLN-049 following FDA meeting
Financial Impact
Pre-revenue clinical-stage biotech; EPS beat of $0.03 per share vs consensus; no revenue or guidance change
Risk Factors
- Clinical trial data may not meet efficacy or safety endpoints
- Regulatory delays or negative FDA feedback could derail timelines
- Pre-revenue company with no near-term commercialization prospects; cash burn risk
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368185 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $15.51 | awaiting T+60 | — | $14.84 (−4.32%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.84 (−3.89%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.84 (−3.89%) |
Sep 22, 2026 5w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.84 (−31.52%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.84 (−27.25%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.84 (−17.33%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.84 (+14.33%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.84 (+23.15%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.84 (+11.75%) |
May 19, 2026 23w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.84 (+4.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers